V. Stewart, S. Hart, C. Hole, D. Mcmurray, J. Hylek et al., Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (atria) study, ):516?21. 2. Go AS, pp.2370-2375, 2001.

W. Kannel, R. Abbott, D. Savage, P. Mcnamara, J. Blackshear et al., Epidemiologic Features of Chronic Atrial Fibrillation Epidemiology and natural history of atrial fibrillation: clinical implications Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study), 1018?22. 4. Chugh SS,371?8. 5. Furberg CD, pp.236-277, 1982.

G. Naccarelli, H. Varker, J. Lin, and K. Schulman, Increasing Prevalence of Atrial Fibrillation and Flutter in the United States, The American Journal of Cardiology, vol.104, issue.11, pp.1534-1543, 2009.
DOI : 10.1016/j.amjcard.2009.07.022

Y. Miyasaka, M. Barnes, B. Gersh, S. Cha, K. Bailey et al., Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, and Implications on the Projections for Future Prevalence. Circulation, pp.119-144, 1980.

S. Chutani, N. Imran, and Y. Kanjwal, Atrial Fibrillation: Current Concepts, Int J Health Sci. janv, vol.2, issue.1, pp.85-90, 2008.

M. Gallagher and J. Camm, Classification of atrial fibrillation, Am J Cardiol. 16 oct, vol.82, issue.8A, 1998.

A. Hrs-focused-updates-incorporated, A. Into-the, and . Esc, Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation. 15 mars, vol.123, issue.10, pp.269-367, 2006.

S. Lévy, M. Maarek, P. Coumel, L. Guize, J. Lekieffre et al., Characterization of Different Subsets of Atrial Fibrillation in General Practice in France : The ALFA Study, Circulation, vol.99, issue.23, pp.3028-3063, 1999.
DOI : 10.1161/01.CIR.99.23.3028

/. Authors, . Task-force-members, A. Camm, G. Lip, D. Caterina et al., 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association, Eur Heart J. 1 nov, vol.33, issue.21, pp.2719-2766, 2012.

A. Jahangir, V. Lee, P. Friedman, J. Trusty, D. Hodge et al., Long-­?Term Progression and Outcomes With Aging in Patients With Lone Atrial Fibrillation A 30-­?Year Follow-­?Up Study. Circulation, pp.3050-3056, 2007.

R. Nieuwlaat, M. Prins, L. Heuzey, J. Vardas, P. Aliot et al., Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on Atrial Fibrillation, European Heart Journal, vol.29, issue.9, pp.1181-1190, 2008.
DOI : 10.1093/eurheartj/ehn139

P. Wolf, R. Abbott, and W. Kannel, Atrial fibrillation as an independent risk factor for stroke: the Framingham Study, Stroke, vol.22, issue.8, pp.983-991, 1991.
DOI : 10.1161/01.STR.22.8.983

B. Brembilla-­?perrot, O. Marçon, F. Chometon, J. Bertrand, A. De-la-chaise et al., Supraventricular tachyarrhythmia as a cause of sudden cardiac arrest, Journal of Interventional Cardiac Electrophysiology, vol.99, issue.2, pp.97-104, 2006.
DOI : 10.1007/s10840-006-9042-4

M. Homoud and I. M. Estes, Shedding new light on the pathophysiology of conversion of paroxysmal atrial fibrillation into persistent atrial fibrillation, American Heart Journal, vol.154, issue.5, pp.801-805, 2007.
DOI : 10.1016/j.ahj.2007.07.017

J. Ferro, Cardioembolic stroke: an update, The Lancet Neurology, vol.2, issue.3, pp.177-88, 2003.
DOI : 10.1016/S1474-4422(03)00324-7

P. Kirchhof, A. Auricchio, J. Bax, H. Crijns, J. Camm et al., Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA), European Heart Journal, vol.28, issue.22, pp.2803-2820, 2007.
DOI : 10.1093/eurheartj/ehm358

M. Gallagher, O. Obel, and A. Camm, Tachycardia-Induced Atrial Myopathy:., Journal of Cardiovascular Electrophysiology, vol.95, issue.9, pp.1065-74, 1997.
DOI : 10.1016/0735-1097(94)00452-V

D. Dries, D. Exner, B. Gersh, M. Domanski, M. Waclawiw et al., Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials, Journal of the American College of Cardiology, vol.32, issue.3, pp.695-703, 1998.
DOI : 10.1016/S0735-1097(98)00297-6

E. Hylek, A. Go, Y. Chang, N. Jensvold, L. Henault et al., Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation, New England Journal of Medicine, vol.349, issue.11, pp.1019-1045, 2003.
DOI : 10.1056/NEJMoa022913

R. Hart, O. Benavente, R. Mcbride, and L. Pearce, Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation, Annals of Internal Medicine, vol.131, issue.7, pp.492-501, 1999.
DOI : 10.7326/0003-4819-131-7-199910050-00003

A. Writing, G. Of, . Investigators, S. Connolly, J. Pogue et al., Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial, Lancet. 10 juin, vol.367, issue.9526, pp.1903-1915, 2006.

C. Van-walraven, R. Hart, D. Singer, A. Laupacis, S. Connolly et al., Oral Anticoagulants vs Aspirin in Nonvalvular Atrial Fibrillation, JAMA, vol.288, issue.19, pp.2441-2449, 2002.
DOI : 10.1001/jama.288.19.2441

J. Mant, F. Hobbs, K. Fletcher, A. Roalfe, D. Fitzmaurice et al., Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial, The Lancet, vol.370, issue.9586, pp.493-503, 2007.
DOI : 10.1016/S0140-6736(07)61233-1

S. Connolly, M. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren et al., Dabigatran versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.361, issue.12, pp.1139-51, 2009.
DOI : 10.1056/NEJMoa0905561

M. Patel, K. Mahaffey, J. Garg, G. Pan, D. Singer et al., Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation, New England Journal of Medicine, vol.365, issue.10, pp.883-91, 2011.
DOI : 10.1056/NEJMoa1009638

URL : https://hal.archives-ouvertes.fr/hal-01038111

H. Inoue and H. Atarashi, Risk factors for thromboembolism in patients with paroxysmal atrial fibrillation, The American Journal of Cardiology, vol.86, issue.8, pp.852-857, 2000.
DOI : 10.1016/S0002-9149(00)01105-X

B. Gage, A. Waterman, W. Shannon, M. Boechler, M. Rich et al., Validation of Clinical Classification Schemes for Predicting Stroke, JAMA, vol.285, issue.22, pp.2864-70, 2001.
DOI : 10.1001/jama.285.22.2864

J. Cairns, S. Connolly, S. Mcmurtry, M. Stephenson, and M. Talajic, Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter, Canadian Journal of Cardiology, vol.27, issue.1, pp.74-90, 2011.
DOI : 10.1016/j.cjca.2010.11.007

B. Gage, C. Van-walraven, L. Pearce, R. Hart, P. Koudstaal et al., Selecting Patients With Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin, Circulation, vol.110, issue.16, pp.2287-92, 2004.
DOI : 10.1161/01.CIR.0000145172.55640.93

R. Lorenzoni, G. Lazzerini, F. Cocci, D. Caterina, and R. , Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) Pilot Study, American Heart Journal, vol.148, issue.1, p.180, 2004.
DOI : 10.1016/j.ahj.2004.02.008

Y. Chan, K. Yiu, K. Lau, Y. Yiu, S. Li et al., The CHADS2 and CHA2DS2-VASc scores predict adverse vascular function, ischemic stroke and cardiovascular death in high-risk patients without atrial fibrillation: Role of incorporating PR prolongation, Atherosclerosis, vol.237, issue.2, pp.504-517, 2014.
DOI : 10.1016/j.atherosclerosis.2014.08.026

R. Pisters, D. Lane, R. Nieuwlaat, C. De-vos, H. Crijns et al., A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation, Chest, vol.138, issue.5, pp.1093-100, 2010.
DOI : 10.1378/chest.10-0134

J. Hirsh, J. Dalen, D. Anderson, L. Poller, H. Bussey et al., Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range, Chest, vol.119, issue.1, pp.8-21, 2001.
DOI : 10.1378/chest.119.1_suppl.8S

B. Eriksson, O. Dahl, L. Ahnfelt, P. Kälebo, J. Stangier et al., Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I, Journal of Thrombosis and Haemostasis, vol.21, issue.Suppl., pp.1573-80, 2004.
DOI : 10.1111/j.1538-7836.2004.00890.x

P. Lancellotti, Scheen AJ [b2] (analytic) LE MÉDICAMENT DU MOIS: Dabigatran étexilate (Pradaxa[sub]®[/sub]): anticoagulant oral, inhibiteur direct sélectif de la thrombine (French), Dabigatran Etixilate Pradaxasub®sub ORAL ANTICOAGULANT Act DIRECT Sel Inhib THROMBIN Engl. cover date, vol.65, issue.10, pp.588-92, 2010.

C. Hermans, Pradaxa[sub]®[/sub] ([sup]D[/sup]abigatran [sup]E[/sup]texilate) et chirurgie orthopédique: pourquoi, pour qui et comment ?

S. Gouvernement-du-canada, Sommaire des motifs de décision (SMD) : Pradax -­? 2008 -­? Santé Canada [Internet], Disponible sur, 2008.

G. Freyburger, G. Macouillard, S. Labrouche, and F. Sztark, Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: Two observational studies in patients undergoing total hip or total knee replacement, Thrombosis Research, vol.127, issue.5, pp.457-65, 2011.
DOI : 10.1016/j.thromres.2011.01.001

M. Samama and F. Depasse, Des anciens aux nouveaux anticoagulants : le rôle du biologiste 1 sept, Ann Biol Clin, vol.67, issue.5, pp.525-559, 2009.

M. Gegu, Chevalet P [b1] (analytic), Piloquet F-­?X [b1] (analytic), Berrut G [b1] (analytic), De Decker L [b1] (analytic). Caractéristiques générales des nouveaux anticoagulants oraux (French), Gen Charact New Oral Anticoagulants Engl. cover date, vol.11, issue.SUP1, pp.4-9, 2013.

G. Soff, A New Generation of Oral Direct Anticoagulants, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.32, issue.3, pp.569-74, 2012.
DOI : 10.1161/ATVBAHA.111.242834

S. Kaatz, P. Kouides, D. Garcia, A. Spyropolous, M. Crowther et al., Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors, American Journal of Hematology, vol.171, issue.Suppl 1, pp.141-146, 2012.
DOI : 10.1002/ajh.23202

K. Bauer, Reversal of antithrombotic agents, American Journal of Hematology, vol.129, issue.Suppl 2, pp.119-145, 2012.
DOI : 10.1002/ajh.23165

O. Grottke, J. Van-ryn, H. Spronk, and R. Rossaint, Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model, Critical Care, vol.18, issue.1, p.27, 2014.
DOI : 10.1093/bja/aes502

G. Lu, F. Deguzman, S. Hollenbach, M. Karbarz, K. Abe et al., A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa, Nature Medicine, vol.48, issue.4, pp.446-51, 2013.
DOI : 10.1038/nm.3102